Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2017

View Archived Issues

BioAxone BioSciences awarded funding to develop sd-rxRNA compound for spinal cord injury

Novartis identifies potent, irreversible myeloperoxidase inhibitors for inflammation

Novel dual Axl/Mer inhibitors designed at Ono Pharmaceutical

First results of PATHWAY study on tezepelumab in severe asthma patients reported

Immunocore and Bill & Melinda Gates Foundation collaborate to develop TCR-based therapeutics

Pluristem Therapeutics' PLX-PAD given FDA fast track status for critical limb ischemia

Emcure Pharmaceuticals discovers novel IDO-1, TDO inhibitors

Novel interleukin-1 receptor-associated kinase 4 inhibitors identified at Bayer

Galapagos presents new sphingosine 1-phosphate receptor antagonists

New serine protease HTRA1 inhibitors disclosed by Roche

CSIR identifies novel aurone alkaloids for tuberculosis

DelMar Pharmaceuticals cleared by FDA to begin clinical studies of VAL-083

Pain Therapeutics receives NIH grants to support Alzheimer's and pain programs

EMA committee recommends approval of 10 mg rivaroxaban for extended prevention of VTE

Moderna Therapeutics reports new development candidates and pipeline progress

Innovate UK awards new funding to Cypralis to develop inhibitors of pancreatic fibrosis

NCI SBIR grant to support phase III study of SGX-301 in CTCL

Phase III MURANO study of venetoclax/rituximab combo in CLL meets primary endpoint

Dupilumab given FDA orphan drug status for eosinophilic esophagitis

Inovio Pharmaceuticals cleared to begin trial of MERS vaccine

New feline model of heart failure with preserved ejection fraction described

FDA approves Trelegy Ellipta for COPD

Cancer Prevention Pharmaceuticals's lead drug for FAP granted fast track status in U.S.

Autolus begins phase I/II studies of AUTO-3 for B-cell ALL and DLBCL

G3 Pharmaceuticals starts research and development program to pursue novel galectin-3 inhibitors

FDA accepts Camurus' NDA for CAM-2038 buprenorphine depots

Bristol-Myers Squibb describes discovery of phase I anti-PD-L1 candidate BMS-986189

FDA approves Xhance for treatment of nasal polyps

Arrowhead updates status of pipeline

BELLUS Health's BLU-5937 significantly reduces cough in preclinical models

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...